Future Treatment Strategies for Triple-Negative Breast Cancer
Closing out his discussion on the management of metastatic triple-negative breast cancer, Aditya Bardia, MD, MPH, considers future treatment strategies that may improve outcomes for patients.
First-Line Treatment for Metastatic TNBC: Pembrolizumab + Chemotherapy
Comprehensive insight on use of first-line pembrolizumab plus chemotherapy in patients diagnosed with metastatic TNBC based on results from the KEYNOTE-355 trial.
Patient Scenario: A 44-Year-Old Woman With Metastatic TNBC
Centering discussion on a patient scenario of metastatic TNBC, Aditya Bardia, MD, MPH, highlights the value of first-line chemoimmunotherapy as a treatment option.
A Brief Overview of Treatment Options for Triple-Negative Breast Cancer
Expert oncologist Aditya Bardia, MD, MPH, shares his perspective on mainstay treatment options for patients diagnosed with metastatic triple-negative breast cancer.
Promising Strategies for Assessing Risk and Detecting Recurrence Earlier
Dr. Bardia discusses promising biomarkers and strategies for helping assess risk and detect recurrence in breast cancer.
Technical and Logistical Challenges Concerning the use of ctDNA Monitoring
Experienced clinician shares insight on potential challenges in the use of ctDNA monitoring.
Practical Clinical Applications for ctDNA Assessment
Clinical pearls addressing the current and potential future applications of ctDNA in breast cancer monitoring strategies.
Data Review: ctDNA Monitoring in Patients with Breast Cancer
Dr. Bardia reviews data from the ASCO 2022 Annual Meeting, focusing on serial postoperative ctDNA monitoring for breast cancer recurrence.
Clinical Evidence Supporting the use of ctDNA to Detect Recurrence
A breast cancer expert provides a brief overview of clinical evidence supporting the use of ctDNA to detect recurrence.
Best Practices for Assessing Risk of Recurrence in Patients with Breast Cancer
Aditya Bardia, MD, MPH shares his approach to assessing breast cancer recurrence risk and monitoring patients during and after treatment.
Optimizing Management of HR+/HER2- BC: Future Directions in Care
Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.
Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition
Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.
Considerations for Use of ADCs in HER2-Low Breast Cancer
A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.
ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04
Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.
Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer
Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.
Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors
Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.
Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs
A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.
Dr. Bardia on the Need for Oral SERDs in ESR1-Mutant ER+ Breast Cancer
Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.
HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?
Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.
Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer
Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.